This phase I/II trial is for patients with advanced pancreatic cancer. The goal is to determine the best dose of immunotherapy drug LMB-100 and see how well it works when given with nab-paclitaxel, a standard chemotherapy used for pancreatic cancer.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario